Florida Oncology and Hematology and American Oncology Network Open Fort Myers Location and Welcome Dr. Magali Van den Bergh
Board-certified physician Magali Van den Bergh, MD joins the physician team.
This author has yet to write their bio.Meanwhile lets just say that we are proud Caroline Hewitt contributed a whooping 42 entries.
Board-certified physician Magali Van den Bergh, MD joins the physician team.
The network’s physicians’ research reports were selected after a thorough peer review process.
American Oncology Network, LLC (AON), a fast-growing network of community-based oncology practices, is pleased to announce the appointment of Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, as the new vice president of clinical innovation, effective July 3.
American Oncology Network, LLC (AON), a fast-growing network of community-based oncology practices, announced this past week that Alti Rahman has joined AON as the company’s chief strategy and innovation officer, effective July 3.
American Oncology Network today announced that the Company has entered into a definitive agreement to receive a strategic growth investment from AEA Growth.
At AON, we’re making great strides toward closing the cancer care gap by ensuring every patient has access to the care needed to help fight their cancer.
Growth within the biosimilar market increases with the adoption of these prescription alternatives by oncologists and other healthcare leaders who are taking the initiative to improve cost-savings for millions of cancer patients. AON is one such organization that is taking the lead to publicize the benefits — including the cost savings — of biosimilars.
Because of the genetic makeup of tumors, cancer affects individuals differently. African Americans report the highest cancer mortality rate, despite the decline in cancer incidence rates, of any other racial population. Here are three facts about cancer in African American communities.
A recent article by The American Journal of Managed Care (AJMC), summarizes an analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition and co-authored by Ruemu E. Birhiray, MD of Hematology Oncology of Indiana showing that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.
AON’s in-house specialty pharmacy announced it has received re-accreditation through URAC, Utilization Review Accreditation Commission. Striving for the highest standards of patient care and safety is the top priority for AON, and accreditations are a means of building trust with patients who come to AON practices for their cancer care and treatments.